Oncobiologics (OTLK) Competitors $1.89 +0.03 (+1.61%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$1.93 +0.04 (+2.12%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. PRQR, NGNE, CRDF, MDWD, EPRX, SOPH, INBX, YMAB, ACIU, and VORShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include ProQR Therapeutics (PRQR), Neurogene (NGNE), Cardiff Oncology (CRDF), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), SOPHiA GENETICS (SOPH), Inhibrx Biosciences (INBX), Y-mAbs Therapeutics (YMAB), AC Immune (ACIU), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors ProQR Therapeutics Neurogene Cardiff Oncology MediWound Eupraxia Pharmaceuticals SOPHiA GENETICS Inhibrx Biosciences Y-mAbs Therapeutics AC Immune Vor Biopharma Oncobiologics (NASDAQ:OTLK) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment. Which has preferable earnings & valuation, OTLK or PRQR? ProQR Therapeutics has higher revenue and earnings than Oncobiologics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologicsN/AN/A-$75.37M-$0.91-2.08ProQR Therapeutics$20.46M11.31-$30.04M-$0.35-6.29 Do analysts rate OTLK or PRQR? Oncobiologics currently has a consensus target price of $9.60, indicating a potential upside of 407.94%. ProQR Therapeutics has a consensus target price of $8.00, indicating a potential upside of 263.64%. Given Oncobiologics' higher possible upside, research analysts clearly believe Oncobiologics is more favorable than ProQR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer OTLK or PRQR? In the previous week, ProQR Therapeutics had 3 more articles in the media than Oncobiologics. MarketBeat recorded 5 mentions for ProQR Therapeutics and 2 mentions for Oncobiologics. ProQR Therapeutics' average media sentiment score of 0.22 beat Oncobiologics' score of 0.00 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncobiologics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, OTLK or PRQR? Oncobiologics has a beta of 0.25, indicating that its share price is 75% less volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Is OTLK or PRQR more profitable? Oncobiologics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -157.04%. Oncobiologics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OncobiologicsN/A N/A -271.12% ProQR Therapeutics -157.04%-53.49%-22.07% Do insiders and institutionals believe in OTLK or PRQR? 11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 4.8% of Oncobiologics shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryProQR Therapeutics beats Oncobiologics on 12 of the 16 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.44M$2.87B$5.50B$8.95BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-2.0820.8026.9720.11Price / SalesN/A286.31425.92119.81Price / CashN/A41.1936.8257.86Price / Book-0.617.487.985.56Net Income-$75.37M-$55.04M$3.16B$248.40M7 Day Performance10.53%2.44%2.36%4.67%1 Month Performance-0.53%1.90%2.15%6.64%1 Year Performance-76.08%4.35%33.78%21.31% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics1.6577 of 5 stars$1.89+1.6%$9.60+407.9%-76.0%$62.44MN/A-2.0820PRQRProQR Therapeutics2.1054 of 5 stars$2.04flat$8.00+292.2%+32.5%$214.63M$20.46M-5.83180News CoverageNGNENeurogene3.6125 of 5 stars$14.95-7.5%$46.17+208.8%-44.9%$213.19M$930K-3.4490CRDFCardiff Oncology1.6864 of 5 stars$3.15flat$9.88+213.5%+77.5%$209.57M$680K-3.4220News CoverageAnalyst ForecastMDWDMediWound1.619 of 5 stars$19.37+0.6%$31.80+64.2%+0.1%$209.39M$20.22M-9.2780EPRXEupraxia Pharmaceuticals2.3829 of 5 stars$5.76+8.7%$11.00+91.0%+123.6%$207.13MN/A-7.5829News CoverageGap UpHigh Trading VolumeSOPHSOPHiA GENETICS2.3499 of 5 stars$3.10+0.3%$7.00+125.8%-21.2%$206.74M$65.17M-3.10520News CoveragePositive NewsINBXInhibrx Biosciences0.9893 of 5 stars$14.27-1.1%N/A+46.5%$206.63M$200K0.12166News CoverageYMABY-mAbs Therapeutics3.2789 of 5 stars$4.51-4.0%$15.60+245.9%-62.7%$204.21M$87.68M-7.05150ACIUAC Immune2.7562 of 5 stars$2.03+1.0%$12.00+491.1%-40.5%$203.83M$28.30M-3.50140VORVor Biopharma3.9425 of 5 stars$1.62+52.8%$5.63+247.4%+164.9%$202.44MN/A-0.98140Options VolumeGap UpHigh Trading Volume Related Companies and Tools Related Companies ProQR Therapeutics Competitors Neurogene Competitors Cardiff Oncology Competitors MediWound Competitors Eupraxia Pharmaceuticals Competitors SOPHiA GENETICS Competitors Inhibrx Biosciences Competitors Y-mAbs Therapeutics Competitors AC Immune Competitors Vor Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OTLK Stock Alerts